WO2007042885A3 - Combinaison therapeutique - Google Patents

Combinaison therapeutique Download PDF

Info

Publication number
WO2007042885A3
WO2007042885A3 PCT/IB2006/002745 IB2006002745W WO2007042885A3 WO 2007042885 A3 WO2007042885 A3 WO 2007042885A3 IB 2006002745 W IB2006002745 W IB 2006002745W WO 2007042885 A3 WO2007042885 A3 WO 2007042885A3
Authority
WO
WIPO (PCT)
Prior art keywords
mek2
mek1
methotrexate
therapeutic combination
specified inhibitor
Prior art date
Application number
PCT/IB2006/002745
Other languages
English (en)
Other versions
WO2007042885A2 (fr
Inventor
Craig Mason Flory
Wayne Daniel Klohs
Mark Bradley Meyer
Bernhardt George Zeiher
Original Assignee
Pfizer Prod Inc
Craig Mason Flory
Wayne Daniel Klohs
Mark Bradley Meyer
Bernhardt George Zeiher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Craig Mason Flory, Wayne Daniel Klohs, Mark Bradley Meyer, Bernhardt George Zeiher filed Critical Pfizer Prod Inc
Publication of WO2007042885A2 publication Critical patent/WO2007042885A2/fr
Publication of WO2007042885A3 publication Critical patent/WO2007042885A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Cette invention concerne une méthode permettant de traiter la polyarthrite rhumatoïde au moyen d'une combinaison comprenant essentiellement du N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-acide glutamique, ou un sel pharmaceutiquement acceptable de celui-ci, et du N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, ainsi que des combinaisons et des compositions pharmaceutiques associées.
PCT/IB2006/002745 2005-10-07 2006-09-25 Combinaison therapeutique WO2007042885A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72454205P 2005-10-07 2005-10-07
US60/724,542 2005-10-07

Publications (2)

Publication Number Publication Date
WO2007042885A2 WO2007042885A2 (fr) 2007-04-19
WO2007042885A3 true WO2007042885A3 (fr) 2007-12-06

Family

ID=37943172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002745 WO2007042885A2 (fr) 2005-10-07 2006-09-25 Combinaison therapeutique

Country Status (3)

Country Link
JP (1) JP2007106762A (fr)
AR (1) AR055677A1 (fr)
WO (1) WO2007042885A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (fr) * 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2005040098A1 (fr) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (fr) * 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2005040098A1 (fr) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRONSTEIN B N: "Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 57, no. 2, June 2005 (2005-06-01), pages 163 - 172, XP002408704, ISSN: 0031-6997 *
HOEKSTRA M ET AL: "Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 62, no. 5, May 2003 (2003-05-01), pages 423 - 426, XP002410166, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
WO2007042885A2 (fr) 2007-04-19
AR055677A1 (es) 2007-08-29
JP2007106762A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
EP1818047A3 (fr) Forme d'administration orale pour principes actifs basiques difficilement solubles
WO2005016876A3 (fr) Inhibiteurs bace-1 amines cycliques a substituant benzamide
NL300650I2 (nl) Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride
EP1734041A3 (fr) Inhibiteurs du recepteur de l'adp plaquettaire
DK1602370T3 (da) Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme
WO2005020899A3 (fr) Derives de cycloalkyamine substitues en tant que modulateurs de l'activite du recepteur de la chimiokine
CA2362499A1 (fr) Combinaisons de formoterol et de furoate de mometasone destinees a l'asthme
CA2429844A1 (fr) Antagonistes de l'hormone de concentration de la melanine (mch) et leur utilisation dans le traitement de l'obesite
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
JP2005514441A5 (fr)
WO2007042885A3 (fr) Combinaison therapeutique
UY27991A1 (es) Derivados de pirrolidona domo inhibidores de maob
WO2006124609A3 (fr) Procedes et compositions pour le traitement de l'arg
JP2009518415A5 (fr)
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004030611A3 (fr) Inhibiteurs non nucleosidiques de transcriptases inverses
RS50534B (sr) Intranazalna formulacija rotigotina
EP1769797A3 (fr) Procédés et compositions utilisant de la cétirizine en combinaison avec des inhibiteurs de leucotriène pour le traitement des affections répondant à l'inhibition des leucotriènes
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
CA2451519A1 (fr) Comprime contenant de la cetirizine et de la pseudoephedrine
WO2005011594A3 (fr) Combinaison de deshydroepiandrosterone ou de sulfate de deshydroepiandrosterone avec un inhibiteur de tyrosine kinase, un antagoniste vis-a-vis du recepteur delta opioide, un antagoniste vis-a-vis du recepteur de neurokinine, ou un inhibiteur de vcam, pour le traitement de l'asthme ou de la maladie obstructive respiratoire
WO2005004915A3 (fr) Compositions contenant meloxicam
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
WO2004071156A3 (fr) Utilisation d'un acide comestible dans des formes posologiques pharmaceutiques solides a dispersion rapide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2